REFERENCES
1. Plumb DC. Maropitant citrate. Plumb's veterinary drug handbook. 6th ed. Ames, Iowa: Blackwell Publishing, 2008;558-560.
2. Gogny M. Principe actif: le maropitant. Nouv Prat Vét Canine Féline 2008;8(39):69-70.
3. Schrickx JA, Fink-Gremmels J. Implications of ABC transporters on the disposition of typical veterinary medicinal products.
Eur J Pharmacol 2008;585(2-3):510-519.
4. Benchaoui HA, Cox SR, Schneider RP, et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist,
in dogs. J Vet Pharmacol Ther 2007;30(4):336-344.
5. Hickman MA, Cox SR, Mahabir S, et al. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant
(Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 2008;31(3):220-229.
6. U.S. or Canadian product information: Cerenia, Pfizer Animal Health, U.S. and Canada.
7. de la Puente-Redondo V, Tingley FD 3rd, Schneider RP, et al. The neurokinin-1 antagonist activity of maropitant, an antiemetic
drug for dogs, in a gerbil model. J Vet Pharmacol Ther 2007;30(4):281-287.
8. Reid IA. Vasoactive peptides. Basic & clinical pharmacology. 9th ed. New York: Lange Medical Books/McGraw-Hill, 2004;281-297.
9. Satake H, Kawada T. Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors.
Curr Drug Targets 2006;7(8):963-974.
10. Diemunsch P, Grélot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60(3):533-546.
11. Freedom of information summary. Original New Animal Drug Application NADA 141-2621. CERENIA (maropitant citrate). Pfizer
Inc. January 2007.
12. Diemunsch P, Grelot L. Substance P antagonists or NK1 receptor antagonists as anti-emetics, in Proceedings. 8th Scientific Meeting European Society of Intravenous Anesthesia (EuroSIVA), 2005.
13. Varty GB, Cohen-Williams ME, Hunter JC. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil
tail suspension test. Behav Pharmacol 2003;14(1):87-95.
|
Featuring Information from:
